Ionway to Build First Production Plant in Poland
By Andrea Figueras
Ionway, the electric-vehicle battery materials joint venture of Umicore and Volkswagen's PowerCo, plans to build its first cathode-active-material (CAM) plant in Nysa, Poland.
The facility will be adjacent to Umicore's existing CAM plant, which will allow Ionway to benefit from Umicore's know-how and to access renewable energy to power its production, the joint venture said over the weekend.
The construction of the plant will start once Ionway gets the corresponding permits, a process that it said is ongoing.
The investment in Poland will create about 900 jobs in Nysa toward the end of the decade and will receive support from the Polish government, which is offering 350 million euros ($370.6 million) in cash grants for a total investment of up to EUR1.7 billion (reduced to EUR1.35 billion after grants) by the end of the decade.
Ionway aims to grow its annual production capacity to 160 gigawatt-hour by the end of the decade, which corresponds to 2.2 million battery-electric vehicles, it said.
Write to Andrea Figueras at andrea.figueras@wsj.com
(END) Dow Jones Newswires
October 09, 2023 01:47 ET (05:47 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks